Breast Cancer Treatment Guidelines and Other Resources for Providers
Breast Cancer Treatment Guidelines
The faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center have developed guidelines on how to best utilize certain treatments recently approved by the Food and Drug Administration (FDA). The guidelines were drafted using data from available clinical trials and presented for feedback and expert consensus to a diverse group of Dana-Farber Brigham physicians, nurses, clinical investigators, lab investigators, translational researchers, administrators, and patient advocates. We are pleased to share our recommended guidelines which may be a helpful reference when using these new agents. In our discussions, we considered:
- Which patients should receive the treatment
- How the medication should be administered
- How the toxicities of the medication should be managed
The reports include reviews of the clinical trials that led to FDA approval as well as the above-mentioned recommendations for patient selection and treatment.
Other Resources for Providers
The faculty in the Breast Oncology Center have also developed other resources for providers, including tip sheets and expert recommendations on managing the care of patients with breast cancer.
Treatment Guideline: Contraception in Patients With a History of Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of contraception in patients with a history of breast cancer.
Treatment Guideline: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.
Treatment Guideline: Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
Treatment Guideline: Use of Bone-Modifying Agents in Patients with Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings in October 2022 and February 2023 to discuss recommendations for bone-modifying agents in patients with breast cancer.
Treatment Guideline: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Treatment Guideline: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
Treatment Guideline: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, October 8, 2021, and June 24, 2022 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
Treatment Guideline: Reflex Testing of OncotypeDX for Early Stage Breast Cancer
The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.
Treatment Guideline: Adjuvant Olaparib for BRCA1/2 Variant Carriers
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.
Expert Review: Communicating Risk and Uncertainty in the Context of Genomic Testing
The Breast Oncology Center developed this reference for providers based on a presentation by Professor Dame Lesley Fallowfield given on October 23, 2024.Additional guidelines will be published here as new agents are approved by the FDA.